GLNG vs ORKA Comparison

Golar LNG Ltd designs, converts, owns, and operates marine infrastructure for the liquefaction of natural gas and provides floating liquefied natural gas (FLNG) services. It offers solutions for gas resource holders to develop and utilize gas reserves, including stranded, associated, flared, or underutilized resources. The company's reportable segments are: i) FLNG: includes the operations of FLNG vessels and projects, and ii) Corporate and other: includes legacy shipping segment activities, vessel management, floating storage and regasification unit services for third parties. The majority of the company's revenue is derived from the FLNG segment. Geographically, it generates the maximum revenue from Cameroon.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.